News
RANI
0.5672
+1.27%
0.0071
Rani Therapeutics: Buy Rating Reaffirmed on Strong Q3, Extended Cash Runway and RT-114 Catalyst; $5 Price Target Unchanged
TipRanks · 20h ago
Rani Therapeutics reports Q3 EPS (4c), consensus (5c)
TipRanks · 20h ago
Rani Q3 Loss Widens On Higher R&D Expenses; RT-114 Phase 1a Expansion Data Due By Year-End
NASDAQ · 1d ago
Rani Therapeutics Holdings, Inc. Reports Third Quarter 2026 Financial Results and FDA Emerging Technology Program Acceptance
NASDAQ · 1d ago
Rani Therapeutics GAAP EPS of -$0.04, revenue of $1.7M
Seeking Alpha · 1d ago
Weekly Report: what happened at RANI last week (1102-1106)?
Weekly Report · 2d ago
Weekly Report: what happened at RANI last week (1026-1030)?
Weekly Report · 11/02 10:26
Weekly Report: what happened at RANI last week (1019-1023)?
Weekly Report · 10/26 10:25
Rani Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 10/22 13:23
Weekly Report: what happened at RANI last week (1012-1016)?
Weekly Report · 10/19 10:25
Why Ericsson Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/15 10:06
Weekly Report: what happened at RANI last week (1005-1009)?
Weekly Report · 10/12 10:31
H.C. Wainwright Sticks to Their Buy Rating for Rani Therapeutics Holdings (RANI)
TipRanks · 10/06 10:36
Rani reports RaniPill acceptance into FDA Emerging Technology Program
TipRanks · 10/05 12:28
Rani Therapeutics Joins FDA Emerging Technology Platform
Benzinga · 10/05 12:09
Weekly Report: what happened at RANI last week (0928-1002)?
Weekly Report · 10/05 10:31
Weekly Report: what happened at RANI last week (0921-0925)?
Weekly Report · 09/28 10:25
H.C. Wainwright Sticks to Their Buy Rating for Rani Therapeutics Holdings (RANI)
TipRanks · 09/21 17:56
Weekly Report: what happened at RANI last week (0914-0918)?
Weekly Report · 09/21 10:25
Weekly Report: what happened at RANI last week (0907-0911)?
Weekly Report · 09/14 10:31
More
Webull provides a variety of real-time RANI stock news. You can receive the latest news about Rani Therapeutics Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).